Subjects: Adults with a type of blood cancer called DLBCL who are receiving a special cancer treatment known as CAR T-cell therapy can join this study. CAR T-cell therapy is a treatment where a patient's own immune cells are modified to attack cancer cells.
Purpose: The study aims to test a new drug, CTO1681, to see if it can help prevent or lessen a side effect called cytokine release syndrome (CRS), which can happen with CAR T-cell therapy. CRS is a condition where the body releases too many cytokines, proteins that help cells communicate, potentially causing fever or other issues.
Process: Participants will take CTO1681 three times a day for 15 days, starting before their CAR T-cell therapy. The study lasts 43 days, with more follow-ups up to six months.
- Participants must provide blood and urine samples and undergo medical tests.
- Safety and how well the drug works will be closely monitored.
- Eligibility requires meeting specific health measures and agreeing to birth control guidelines.